Related Experiment Videos
Efficacy of magnesium citrate cathartic in pediatric toxic ingestions
1Department of Pediatrics, Children's Hospital, Harvard Medical School, Massachusetts Poison Control System, Boston.
Insights
Magnesium citrate effectively reduced gastrointestinal transit time for activated charcoal in pediatric toxic ingestions. Higher magnesium citrate doses showed greater efficacy in accelerating charcoal stool passage.
Area of Science:
- Pediatric Emergency Medicine
- Clinical Pharmacology
- Toxicology
Background:
- Activated charcoal is crucial for managing acute toxic ingestions in children.
- Gastrointestinal transit time of activated charcoal can influence its efficacy.
- Magnesium citrate is a commonly used osmotic laxative.
Purpose of the Study:
- To evaluate the impact of varying magnesium citrate doses on the gastrointestinal transit time of activated charcoal in pediatric patients.
- To determine if magnesium citrate administration can accelerate the elimination of activated charcoal.
Main Methods:
- Prospective, randomized clinical trial involving children (1 month to 6 years) with acute toxic ingestions.
- Participants received activated charcoal (1 g/kg) with one of four magnesium citrate doses (0, 4, 6, or 8 mL/kg).
- Primary outcome was the time to the first activated charcoal-containing stool, assessed via follow-up.
Main Results:
- Sixty-four children were enrolled in the study.
- Median times to first charcoal stool were significantly reduced with magnesium citrate administration (19.5h for 0 mL/kg vs. 13.0h, 14.0h, and 12.0h for 4, 6, and 8 mL/kg, respectively).
- Kruskal-Wallis analysis revealed statistically significant intergroup differences (P = .0035).
Conclusions:
- Magnesium citrate administration significantly shortens gastrointestinal transit time for activated charcoal in children treated for toxic ingestions.
- The findings suggest a potential benefit of magnesium citrate in enhancing activated charcoal's elimination.
- Further research is warranted to establish the clinical significance and optimal dosing of magnesium citrate in this context.
Study Objective:
To investigate the efficacy of magnesium citrate in reducing gastrointestinal transit time of activated charcoal in children.
Design:
A prospective, randomized, clinical comparison of four magnesium doses.
Setting:
Urban children's hospital emergency department.
Participants:
Children aged 1 month to 6 years who presented for management of an acute toxic ingestion.
Intervention:
Each child received 1 g/kg activated charcoal combined with a randomly assigned dose of a 6% solution of magnesium citrate: 0 mL/kg, 4 mL/kg (standard recommended dose), 6 mL/kg, or 8 mL/kg. The primary outcome measure was the interval to first activated charcoal-containing stool, which was determined by follow-up telephone call or review of the medical record.
Results:
Sixty-four children were enrolled. Median times to first charcoal stool were 19.5 hours (0 mL/kg), 13.0 hours (4 mL/kg), 14.0 hours (6 mL/kg), and 12.0 hours (8 mL/kg). Intergroup differences were significant by Kruskal-Wallis analysis of variance (P = .0035).
Conclusion:
Magnesium citrate reduces gastrointestinal transit times of activated charcoal stools when administered to children who receive activated charcoal for a toxic ingestion. Further study is needed to determine the clinical value of this reduction.